Should I buy or sell RVL Pharmaceuticals stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for RVL Pharmaceuticals in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" RVLP shares. View RVLP analyst ratings or view top-rated stocks .

What is RVL Pharmaceuticals' stock price target for 2024?

1 equities research analysts have issued 1-year price objectives for RVL Pharmaceuticals' shares. Their RVLP share price targets range from $2.00 to $3.00. On average, they predict the company's share price to reach $2.50 in the next twelve months. This suggests a possible upside of 68,393.2% from the stock's current price. View analysts price targets for RVLP or view top-rated stocks among Wall Street analysts .

How have RVLP shares performed in 2023?

RVL Pharmaceuticals' stock was trading at $1.12 at the beginning of 2023. Since then, RVLP shares have decreased by 99.7% and is now trading at $0.0037. View the best growth stocks for 2023 here .

When is RVL Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 30th 2023. View our RVLP earnings forecast .

How were RVL Pharmaceuticals' earnings last quarter?

RVL Pharmaceuticals plc (NASDAQ:RVLP) posted its quarterly earnings data on Monday, March, 20th. The company reported ($0.18) earnings per share for the quarter, missing the consensus estimate of ($0.15) by $0.03. The business had revenue of $9.81 million for the quarter, compared to the consensus estimate of $12.10 million. RVL Pharmaceuticals had a negative trailing twelve-month return on equity of 130.22% and a negative net margin of 184.91%. During the same period last year, the company earned ($0.26) earnings per share.

Who are RVL Pharmaceuticals' major shareholders?

RVL Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional investors include Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Foundation Harsaul and Ltd Altchem. View institutional ownership trends .

How do I buy shares of RVL Pharmaceuticals?

Shares of RVLP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

RVL Pharmaceuticals Stock Price, News & Analysis (NASDAQ:RVLP)

$0.0037

0.00 (0.00%)

(As of 11/27/2023 ET)

Compare

Today's Range: $0.0027
▼
$0.0044
50-Day Range: $0.00
▼
$0.19
52-Week Range: $0.03
▼
$1.91

Volume: 2.77 million shs
Average Volume: N/A
Market Capitalization: $406,646.50

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $2.50

RVL Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 68,393.2% Upside
$2.50 Price Target
Short Interest: N/A
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: Selling Shares
$348,059 Sold Last Quarter
Proj. Earnings Growth: Growing
From ($0.46) to ($0.42) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.73 out of 5 stars

3.5

Analyst's Opinion

Consensus Rating
RVL Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $2.50, RVL Pharmaceuticals has a forecasted upside of 68,393.2% from its current price of $0.00.
Amount of Analyst Coverage
RVL Pharmaceuticals has received no research coverage in the past 90 days.

N/A

Short Interest

Short Interest
There is no current short interest data available for RVLP.

0.0

Dividend Strength

Dividend Yield
RVL Pharmaceuticals does not currently pay a dividend.
Dividend Growth
RVL Pharmaceuticals does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for RVLP.

0.0

News and Social Media Coverage

Search Interest
Only 2 people have searched for RVLP on MarketBeat in the last 30 days. This is a decrease of -98% compared to the previous 30 days.
MarketBeat Follows
Only 1 people have added RVL Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -90% compared to the previous 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, RVL Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $348,059.00 in company stock.
Percentage Held by Insiders
Only 4.40% of the stock of RVL Pharmaceuticals is held by insiders.
Percentage Held by Institutions
Only 24.20% of the stock of RVL Pharmaceuticals is held by institutions.

1.3

Earnings and Valuation

Earnings Growth
Earnings for RVL Pharmaceuticals are expected to grow in the coming year, from ($0.46) to ($0.42) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of RVL Pharmaceuticals is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of RVL Pharmaceuticals is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
RVL Pharmaceuticals has a P/B Ratio of 0.01. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About RVL Pharmaceuticals Stock (NASDAQ:RVLP)

RVL Pharmaceuticals plc, a specialty pharmaceutical company, focuses on the development and commercialization of pharmaceutical products that target markets with underserved patient populations in the ocular and medical aesthetics therapeutic areas in the United States, Argentina, and Hungary. It is commercializing Upneeq (RVL-1201), an oxymetazoline hydrochloride ophthalmic solution, for the treatment of acquired blepharoptosis, or low-lying eyelid in adults. The company was formerly known as Osmotica Pharmaceuticals plc and changed its name to RVL Pharmaceuticals plc in January 2022. RVL Pharmaceuticals plc is headquartered in Bridgewater, New Jersey.

RVLP Stock Price History

30 days | 90 days | 365 days | Advanced Chart

RVLP Stock News Headlines

October 13, 2023 | marketwatch.com

RVL Pharmaceuticals Shares Plummet 50% as Subsidiaries File For Bankruptcy

October 12, 2023 | benzinga.com

Specialty Pharma Firm RVL Pharmaceuticals Subsidiaries File for Bankruptcy

November 29, 2023 | Autonomix (Ad)

[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity

Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com

October 12, 2023 | markets.businessinsider.com

RVL Subsidiaries To Effectuate Change Of Control; RVLP Ordinary Shares Expected To Be Cancelled

October 12, 2023 | finance.yahoo.com

RVL Pharmaceuticals Subsidiaries File for Bankruptcy

October 6, 2023 | investorplace.com

Why Is RVL Pharmaceuticals (RVLP) Stock Up 28% Today?

August 23, 2023 | finance.yahoo.com

Unmasking the Value Trap: A Deep Dive into RVL Pharmaceuticals PLC

August 23, 2023 | finance.yahoo.com

RVL Pharmaceuticals plc to Present at the H.C. Wainwright 25th Annual Global Investment Conference

November 29, 2023 | Autonomix (Ad)

[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity

August 21, 2023 | markets.businessinsider.com

RVL Pharmaceuticals (RVLP) Gets a Buy from H.C. Wainwright

August 16, 2023 | benzinga.com

Crude Oil Falls Sharply; RVL Pharmaceuticals Shares Plummet

August 16, 2023 | msn.com

RVLP: Second Quarter Results

August 16, 2023 | marketwatch.com

RVL Pharmaceuticals Shares Hit New Lows After Stock Sale >RVLP

August 16, 2023 | msn.com

RVL Pharmaceuticals shares fall after pricing $5M stock offering

August 16, 2023 | finance.yahoo.com

Downgrade: Here's How Analysts See RVL Pharmaceuticals plc (NASDAQ:RVLP) Performing In The Near Term

August 16, 2023 | finance.yahoo.com

RVL Pharmaceuticals plc Announces $5 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules

August 15, 2023 | finance.yahoo.com

Q2 2023 RVL Pharmaceuticals PLC Earnings Call

August 14, 2023 | msn.com

RVLP: Revenue Dip Prompts Spending Reversal

August 14, 2023 | finance.yahoo.com

RVL Pharmaceuticals plc Reports Second Quarter 2023 Financial Results; Provides Update on Strategic Business Review

July 20, 2023 | finance.yahoo.com

Insiders Re-Evaluate Their US$1.6m Stock Purchase As RVL Pharmaceuticals Falls To US$43m

July 5, 2023 | msn.com

RVL Pharma (NASDAQ:RVLP) Rises on Mulling A Strategic Transaction

July 5, 2023 | benzinga.com

RVL Pharmaceuticals shares are trading higher after the company said it has been considering certain strategic alternatives.

June 15, 2023 | finance.yahoo.com

RVL Pharmaceuticals plc Announces Result of Proposal to Approve a Waiver of Offer Obligations under Rule 9 of the Irish Takeover Rules at Annual General Meeting

June 2, 2023 | finance.yahoo.com

Shareholders in RVL Pharmaceuticals (NASDAQ:RVLP) are in the red if they invested three years ago

May 13, 2023 | finance.yahoo.com

Time To Worry? Analysts Just Downgraded Their RVL Pharmaceuticals plc (NASDAQ:RVLP) Outlook

May 12, 2023 | finance.yahoo.com

RVLP: First Quarter Results

May 12, 2023 | msn.com

RVL Pharmaceuticals: Q1 Earnings Insights

See More Headlines

Receive RVLP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for RVL Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/20/2023
Today: 11/28/2023
Next Earnings (Estimated): 11/30/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:RVLP
CUSIP: N/A
CIK: 1739426
Web: www.osmotica.com
Phone: (908) 809-1300
Fax: N/A
Employees: 125
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $2.50
High Stock Price Target: $3.00
Low Stock Price Target: $2.00
Potential Upside/Downside: +68,393.2%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.70)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-51,690,000.00
Net Margins: -184.91%
Pretax Margin: -185.66%
Return on Equity: -130.22%
Return on Assets: -47.70%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 0.38
Quick Ratio: 0.36

Sales & Book Value

Annual Sales: $49.72 million
Price / Sales: 0.01
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.51 per share
Price / Book: 0.01

Miscellaneous

Outstanding Shares: 111,410,000
Free Float: 106,504,000
Market Cap: $406,646.50
Optionable: Optionable
Beta: 1.32

7 Energy Stocks to Buy and Hold Forever

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives

Mr. Brian A. Markison (Age 64)
Chairman, President, CEO & Principal Financial Officer
Comp: $525k
Mr. James D. Schaub (Age 41)
Executive VP & COO
Comp: $367.2k
Mr. Christopher A. Klein (Age 58)
General Counsel & Secretary
Comp: $367.2k
Mr. Michael J. DePetris (Age 46)
Principal Accounting Officer
Mr. Jarret Miller
Executive Vice President of Human Resources

Key Competitors

View All Competitors

Insiders

View All Insider Transactions

RVLP Stock Analysis - Frequently Asked Questions

Should I buy or sell RVL Pharmaceuticals stock right now?: 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for RVL Pharmaceuticals in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" RVLP shares.
View RVLP analyst ratings or view top-rated stocks.
What is RVL Pharmaceuticals' stock price target for 2024?: 1 equities research analysts have issued 1-year price objectives for RVL Pharmaceuticals' shares. Their RVLP share price targets range from $2.00 to $3.00. On average, they predict the company's share price to reach $2.50 in the next twelve months. This suggests a possible upside of 68,393.2% from the stock's current price.
View analysts price targets for RVLP or view top-rated stocks among Wall Street analysts.
How have RVLP shares performed in 2023?: RVL Pharmaceuticals' stock was trading at $1.12 at the beginning of 2023. Since then, RVLP shares have decreased by 99.7% and is now trading at $0.0037.
View the best growth stocks for 2023 here.
When is RVL Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, November 30th 2023.
View our RVLP earnings forecast.

How were RVL Pharmaceuticals' earnings last quarter?: RVL Pharmaceuticals plc (NASDAQ:RVLP) posted its quarterly earnings data on Monday, March, 20th. The company reported ($0.18) earnings per share for the quarter, missing the consensus estimate of ($0.15) by $0.03. The business had revenue of $9.81 million for the quarter, compared to the consensus estimate of $12.10 million. RVL Pharmaceuticals had a negative trailing twelve-month return on equity of 130.22% and a negative net margin of 184.91%. During the same period last year, the company earned ($0.26) earnings per share.
Who are RVL Pharmaceuticals' major shareholders?: RVL Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional investors include Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Foundation Harsaul and Ltd Altchem.
View institutional ownership trends.
How do I buy shares of RVL Pharmaceuticals?: Shares of RVLP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:RVLP) was last updated on 11/29/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

RVL Pharmaceuticals Stock Price, News & Analysis (NASDAQ:RVLP)

RVL Pharmaceuticals MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Short Interest

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About RVL Pharmaceuticals Stock (NASDAQ:RVLP)

RVLP Stock Price History

RVLP Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders

RVLP Stock Analysis - Frequently Asked Questions

Overall MarketRank^™